Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer
Clinical trial NCT05218629 · UNKNOWN
Trial details
- NCT number
- NCT05218629
- Sponsor
- Qingdao Central Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-01
- Primary completion
- 2024-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.